跳至主要内容
临床试验/JPRN-UMIN000017823
JPRN-UMIN000017823已完成未知

A study to assess the safety and efficacy of rifampicin for progressive familial intrahepatic cholestasis (PFIC) and benign recurrent intrahepatic cholestasis (BRIC) - A study to assess the safety and efficacy of rifampicin for progressive familial intrahepatic cholestasis (PFIC) and benign recurrent intrahepatic cholestasis (BRIC)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University0 个研究点目标入组 3 人开始时间: 2015年6月5日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
3

研究概览

简要总结

o patient was enrolled.

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Patients with past histories of hypersensitivity reaction against rifampicin. 2. Patients currently receiving medications that are known to interact with rifampicin (drug for HIV infection, voriconazole, pradicantel, tadalafil, telaprevir, or simeprevir etc.) 3. Patients with serious active bacterial infection as sepsis.

研究者

发起方
Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University

相似试验